Reimbursement Series: Anchors Affordable Breakthroughs – AIFA and TLV Expand European Coverage
Sweden expands reimbursement decisions driving biotech access and patient impact.
Market Access
NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
NICE accelerates breakthrough framework for complex liver diseases
NICE drives innovation, reshaping MASH evaluations with transformative guidance.
Poland Makes Historic Leap in Healthcare: Record Number of New Therapies Now Reimbursed
Poland’s Ministry of Health has announced its largest-ever reimbursement list update
Focus Brief: Market Access Weekly September 1 to 7, 2025
Global market access shifts: HTA speed, UK pricing, digital disruption.
NCPE Recommends Conditional Access for Omeprazole
NCPE recommends Omeprazole Appizped for reimbursement eligibility.
NCPE Recommends Vabysmo, Signaling Retinal Policy Shift
NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.
New Reimbursement Strategy Boosts Ambulatory Pay
New partnership advances reimbursement strategy for private practices.
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
South Korea’s Drug Pricing Reforms Reshape Market Access Landscape
South Korea’s new pharma pricing reforms reward innovation and expand access for industry.